Prevelance Study Of Celiac Disease(Cd) In Type 1 Diabetes Patients

Authors

  • Maher Madi Tishreen University
  • Ruba Salman Tishreen University
  • Ali Ghosa Tishreen University

Abstract

Background : : Celiac disease is relatively common chronic disease(1_2%) of the world's population, and can be present at any age. It's an autoimmune disease such as Type 1 diabetes. Early diagnosis of celiac disease in type 1 diabetes patients protects against irreversible complications such as growth failure and short suture and helps control blood sugar and prevent complications.

Patients and Methods : we conducted a cross sectional study to investigate celiac disease in patients with type 1 diabetes who attended Tishreen University Hospital in Lattakia for a year between 2020-2021 after obtaining the approval. The study included 81 patients with type 1 diabetes according to the entry criteria. A blood analysis was performed for all patients included anti ttg igA, total igA, glucose, calcium, hemoglobin and albumin, with a detailed clinical history of digestive symptoms taken.

Results : The prevalence of celiac disease among patients with type 1 diabetes in our study which included 81 patients, reached 9.8%, which is in agreement with the rates in the reference studies that ranged between 5.5% and 10.4%, and above the global rates for the prevalence of celiac disease in the general population. It was also found that it is not possible to rely on clinical symptoms to determine who are the patients with type 1 diabetes who should be investigated for celiac disease.

Conclusion :  Early detection of celiac disease should be done in all patients with type 1 diabetes, regardless of clinical symptoms or laboratory values, because early detiction of associated celiac disease protects against irreversible complications .

Author Biographies

Maher Madi, Tishreen University

Professor - Faculty of Human Medicine

Ruba Salman, Tishreen University

Assistant Professor - Faculty of Human Medicine

Ali Ghosa, Tishreen University

Postgraduate Student - Faculty of Human Medicine

Downloads

Published

2022-03-29

How to Cite

1.
ماضي م, سلمان ر, غصه ع. Prevelance Study Of Celiac Disease(Cd) In Type 1 Diabetes Patients. Tuj-hlth [Internet]. 2022Mar.29 [cited 2024Nov.24];44(1):249-5. Available from: https://journal.tishreen.edu.sy/index.php/hlthscnc/article/view/12020

Issue

Vol. 44 No. 1 (2022): Tishreen University Journal for Research and Scientific Studies - Health Sciences Series

Section

Master student researches

License

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

The authors retain the copyright and grant the right to publish in the magazine for the first time with the transfer of the commercial right to Tishreen University Journal for Research and Scientific Studies - Health Sciences Series

 Under a CC BY- NC-SA 04 license that allows others to share the work with of the work's authorship and initial publication in this journal. Authors can use a copy of their articles in their scientific activity, and on their scientific websites, provided that the place of publication is indicted in  Tishreen University Journal for Research and Scientific Studies - Health Sciences Series   .  The Readers have the right to send, print and subscribe to the initial version of the article, and the title of  Tishreen University Journal for Research and Scientific Studies - Health Sciences Series  Publisher

journal uses a CC BY-NC-SA license which mean

You are free to:

  • Adapt — remix, transform, and build upon the material
  •  
  • The licensor cannot revoke these freedoms as long as you follow the license terms.

 

  • Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
  • NonCommercial — You may not use the material for commercial purposes.
  • ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
  • No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.